You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Comment on journal review of ‘Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture’
  1. Lee L Lanza, ScD
  1. Lisa J McQuay, MBioinf
  1. Kenneth J Rothman, DrPH
  1. Henry G Bone, MD
  1. Andrew M Kaunitz, MD
  1. Zeev Harel, MD
  1. Quazi Ataher, PhD
  1. Douglas Ross, MD
  1. Philip L Arena, BSPharm
  1. Kevin D Wolter, * MD
  1. Director of Epidemiology, RTI Health Solutions, Waltham, MA, USA; llanza@rti.org
  2. Senior Research Epidemiologist, RTI Health Solutions, Research Triangle Park, NC, USA; ljmcquay@rti.org
  3. Vice-President for Epidemiology Research, RTI Health Solutions, Research Triangle Park, NC, USA; krothman@rti.org
  4. Section Chief of the Endocrinology Department, St John Hospital and Medical Center; Michigan Bone & Mineral Clinic, Detroit, MI, USA; hgbone.md@att.net
  5. Professor and Associate Chair, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, FL, USA; andrew.kaunitz@jax.ufl.edu
  6. Professor of Pediatrics, Division of Adolescent Medicine/Hasbro Children's Hospital and Department of Pediatrics/Warren Alpert Medical School, Brown University, Providence, RI, USA; ZHarel@Lifespan.org
  7. Director of Epidemiology, Pfizer Inc., Collegeville, PA, USA; quazi.ataher@pfizer.com
  8. Senior Director of Medical Affairs, Pfizer Inc., Collegeville, PA, USA; douglas.ross@pfizer.com
  9. Director of Safety Surveillance, Pfizer Inc., New York, NY, USA; philip.l.arena@pfizer.com
  10. Senior Director of Clinical Development, Pfizer Inc., New York, NY, USA; kevin.d.wolter@pfizer.com
  1. * Corresponding author

https://doi.org/10.1136/jfprhc-2013-100759

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Curry for an accurate summary1 of our study entitled ‘Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture’.2 Nevertheless, we do not recommend more selective use of depot medroxyprogesterone acetate (DMPA) on account of fracture risk, as we believe that this recommendation would reduce access to an effective, safe contraceptive without actually reducing fracture risk. As we reported, in those subjects with at least 6 months of pre-DMPA medical history (176 pre-treatment fractures …

    View Full Text

    Footnotes

    • Competing interests Doctors Ataher, Arena, Ross and Wolter are employees of Pfizer, Inc.

    • Provenance and peer review Not commissioned; internally peer reviewed.